GERN Geron Corporation

1.84
-0.12  -6%
Previous Close 1.96
Open 1.42
Price To Book 2.75
Market Cap 368,665,800
Shares 200,361,848
Volume 20,673,905
Short Ratio
Av. Daily Volume 2,552,761
Stock charts supplied by TradingView

NewsSee all news

  1. Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants

    MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public

  2. Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

    MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock and

  3. Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates

    Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in first quarter

  4. Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 70,000 shares of Geron common stock as an inducement to a newly-hired employee in connection

  5. Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress

    Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data and analyses related to imetelstat, the Company's first-in-class

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2H 2022.
Imetelstat - IMerge Study
Myelodysplastic syndromes
Phase 3 trial to commence 1Q 2021 with interim analysis in 1H 2023 and final analysis in 1H 2024.
Imetelstat
Myelofibrosis

Latest News

  1. Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants

    MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public

  2. Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

    MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock and

  3. Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates

    Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in first quarter

  4. Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 70,000 shares of Geron common stock as an inducement to a newly-hired employee in connection

  5. Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress

    Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data and analyses related to imetelstat, the Company's first-in-class

  6. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 500,000 shares of Geron common stock as inducements to two newly-hired employees in connection

  7. Geron to Present at Needham Virtual Healthcare Conference

    MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at

  8. Geron Provides COVID-19 Related Business Update

    MENLO PARK, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from its March 12 year-end

  9. Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones

    MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic

  10. Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

    Geron Corporation (NASDAQ:GERN) today announced that it will release its fourth quarter and full year 2019 financial results after the market closes on Thursday, March 12, 2020 via press release, which will be available

  11. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 100,000 shares of Geron common stock as inducements to two newly-hired employees in connection

  12. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 98,000 shares of Geron common stock as inducements to two newly-hired employees in connection

  13. Geron Announces 2019 Accomplishments and Key Development Priorities for 2020

    Geron Corporation (NASDAQ:GERN), a late-stage clinical development biopharmaceutical company, today announced 2019 accomplishments and key development priorities for 2020. The Company is currently enrolling patients in

  14. Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 100,000 shares of Geron common stock as an inducement to a newly-hired employee in connection

  15. Geron Conducts End of Phase 2 Meeting for Imetelstat in Relapsed/Refractory Myelofibrosis

    Geron Corporation (NASDAQ:GERN) today announced that the Company has conducted an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of the IMbark Phase 2 clinical trial of

  16. Geron Reports Two Poster Presentations at American Society of Hematology Annual Meeting

    Geron Corporation (NASDAQ:GERN) today announced that two posters related to imetelstat, the Company's first-in-class telomerase inhibitor, were presented at the 61st American Society of Hematology (ASH) Annual Meeting

  17. Geron Announces Appointment of New Executive to Focus on Corporate Strategy

    Geron Corporation (NASDAQ:GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate Strategy and Chief Commercial Officer. With this appointment, all functions of a fully-integrated,

  18. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MENLO PARK, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 150,000 shares of Geron common stock as

  19. Geron Corporation Reports Third Quarter 2019 Financial Results and Recent Events

    MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as recent events. The

  20. Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting

    MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that two abstracts related to imetelstat, the Company's first-in-class telomerase inhibitor, have been accepted for

  21. Geron to Announce Third Quarter Financial Results on November 6, 2019

    MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that it will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019

  22. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MENLO PARK, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of Geron common stock as

  23. Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

    MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class

  24. Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis

    MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the

  25. Geron to Present at 2019 Cantor Global Healthcare Conference

    MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at

  26. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MENLO PARK, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as